Rituximab in maintaining remission in adults with podocytopathy.

Raja RamachandranJoyita BharatiRitambhra NadaRanjana MinzHarbir Singh Kohli

Published in: Nephrology (Carlton, Vic.) (2020)

CD19-targeted rituximab therapy is safe and efficacious in the management of SD/SR adult podocytopathy. Also, rituximab is effective in maintaining remission in treatment naïve adult SD or FR podocytopathy.

Keyphrases

diffuse large b cell lymphoma
chronic lymphocytic leukemia
hodgkin lymphoma
disease activity
ulcerative colitis
cancer therapy
childhood cancer
stem cells
systemic lupus erythematosus
nk cells